AN2 Therapeutics Signs License Agreement with the University

License enables advancement of AN2-502998 , a boron-based small molecule therapeutic under development for the treatment of Chagas disease



IND-enabling preclinical studies well underway in...

Related Keywords

United States , America , Eric Easom , Rick Tarleton , University Of Georgia , World Health Organization , Therapeutics Inc , Pfizer , University Of Georgia Research Foundation , Nasdaq , Department Of Cellular Biology , Wellcome , Anacor Pharmaceuticals Inc , Georgia Research Foundation , Anacor Pharmaceuticals , Professor Rick Tarleton , Chief Executive Officer , Regents Professor , Emerging Global Diseases , Cellular Biology , Neglected Tropical Disease , Latin America , Private Securities Litigation Reform Act , Markets ,